Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3 CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
Yuwen Zhu and Lieping Chen
See related article, p. 44

6 Targeting Metabolic Scavenging in Pancreatic Cancer
Costas A. Lyssiotis and Lewis C. Cantley
See related article, p. 120

CCR Perspectives in Drug Approval

9 Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

CCR Drug Updates

15 Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
Ian Krop and Eric P. Winer

Molecular Pathways

21 Molecular Pathways: SWI/SNF (BAF)Complexes Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights
Xiaofeng Wang, Jeffrey R. Haswell, and Charles W.M. Roberts

28 Molecular Pathways: Sterols and Receptor Signaling in Cancer
Linara Gabitova, Andrey Gorin, and Igor Astsaturov

Review

35 Noncoding RNAs in Prostate Cancer: The Long and the Short of It
Eva M. Bolton, Alexandra V. Tuzova, Anna L. Walsh, Thomas Lynch, and Antoinette S. Perry

HUMAN CANCER BIOLOGY

44 CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
Qunrui Ye, De-Gang Song, Mathilde Foussin, Tori Yamamoto, Andrew Best, Chunsheng Li, George Coukos, and Daniel J. Powell Jr.
See related article, p. 3

56 αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

68 A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

76 HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
Vikas Sehdev, Ahmed Karsha, Janet Arras, Dunfa Peng, Mohammed Soutto, Jeffrey Ecsedy, Alexander Zaika, Abbes Belkhiri, and Wael El-Rifai

87 Discrete Molecular Classes of Ovarian Cancer Suggestive of Unique Mechanisms of Transformation and Metastases
Nilesh L. Gardi, Tejaswini U. Deshpande, Swapnil C. Kamble, Sagar R. Badhe, and Sharmila A. Bapat

100 Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
Olga Dakhova, David Rowley, and Michael Ittmann

CANCER THERAPY: PRECLINICAL

110 The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radioresistance of Pancreatic Carcinoma Cells
Thomas J. Hayman, Amy Wahba, Barbara H. Rath, Heeskyong Bae, Tamalee Kramp, Uma T. Shankavaram, Kevin Camphausen, and Philip J. Tofilon
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Claudia C.S. Chini, Anatilde M. Gonzalez Guerrico, Verónica Nin, Juliana Camacho-Pereira, Carlos Escande, María Theresia Barrosa, and Eduardo N. Chini
See related article, p. 6

Interleukin-7 Mediates Selective Expansion of Tumor-directed Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Serena K. Perna, Daria Pagliara, Aruna Mahendravada, Hao Liu, Malcolm K. Brenner, Barbara Savoldo, and Gianpietro Dotti

Transient Activation of Hedgehog Pathway Rescued Irradiation-Induced Hyposalivation by Preserving Salivary Stem/Progenitor Cells and Parasympathetic Innervation
Bo Hai, Lizheng Qin, Zhenhua Yang, Qingguo Zhao, Lei Shangguan, Xinyu Ti, Yanqiu Zhao, Sangroh Kim, Dharianpathy Rangaraj, and Fei Liu

Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Xianping Shi, Xin Chen, Xiaofen Li, Xiaoying Lan, Chong Zhao, Shoutuing Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, Wenbin Song, Ping Zhou, Shunqing Wang, Li Xu, Xuejun Wang, and Jinbao Liu

AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Philip D. Dunne, Darragh C. McArt, Jaime K. Blayney, Murugan Kalimuthu, Samandra Greer, Tingting Wang, Supriya Srivastava, Chee Wei Ong, Ken Arthur, Maurice Loughrey, Keara Redmond, Daniel B. Longley, Manuel Salto-Tellez, Patrick G. Johnston, and Sandra Van Schaeybroeck

Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
Vijaya L. Damaraju, Tara Scriver, Delores Mowles, Michelle Kuzma, Anderson J. Ryan, Carol E. Cass, and Michael B. Sawyer

Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Ji Liang, Yuji Piao, Lindsay Holmes, Gregory N. Fuller, Verlene Henry, Ningyi Tiao, and John F. de Groot

Direct Inhibition of Retinoblastoma Phosphorylation by Nimibolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth
Swagata Karkare, Rishi Raj Chhipa, Jane Anderson, Xiaolu Liu, Heather Henry, Anjelika Gasilina, Nicholas Nassar, Jayeeta Roychoudhury, Jason P Clark, Ashish Kumar, Giovanni M. Paulenti, Pradip K. Ghosh, and Biplab Dasgupta

CANCER THERAPY: CLINICAL

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haïoun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard, and Bertrand Coiffier

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase Trine Zeeberg Iversen, Lotte Engell-Noerregaard, Eva Ellebaek, Rikke Andersen, Stine Klaer Larsen, Jon Bjoem, Claus Zeyher, Cécile Gouttefangeas, Birthe Moerk Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads Hald Andersen, and Inge Marie Svane

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscienly, Antonin Levy, Christophe Massard, Rastislav Balbeda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammar, and Jean-Charles Soria
PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

253 Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones, Jamie P. Nourse, Colm Keane, Atul Bhatnagar, and Maher K. Gandhi

265 Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Justin Guinney, Charles Ferté, Jonathan Dry, Robert McEwen, Gilles Manceau, K.I. Kao, Kai-Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Dureux, Jean-Charles Soria, Stephen Friend, Jonathan Derry, and Pierre Laurent-Puig

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacr.org
For more information please visit www.aacrjournals.org

ABOUT THE COVER
The cover shows immunofluorescent labeling of the blood-brain barrier marker GLUT-1 (red) in cultured human brain microvascular endothelial cells. Nuclei (blue) were stained with DAPI. For details, see the article by Malin and colleagues on page 56 of this issue.
Clinical Cancer Research

20 (1)


Updated version

Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/20/1

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/20/1.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.